Patents by Inventor Frank Zocher
Frank Zocher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8765910Abstract: The invention relates to a method for producing C-terminal amidated dibasic or polybasic peptides, consisting in reacting two peptides in the presence of trypsin biologically active enzymes and, if necessary, in purifying the thus obtainable compounds of formula (I) by means of protein chemistry.Type: GrantFiled: September 13, 2006Date of Patent: July 1, 2014Assignee: Sanofi-Aventis Deutschland GmbHInventors: Sebastian Rissom, Paul Habermann, Christophe Salagnad, Frank Zocher, Laure Landric-Burtin
-
Patent number: 8410048Abstract: The invention relates to a method for producing a type of insulin by genetically engineering a precursor thereof and converting said precursor to the respective insulin in an enzyme-catalyzed ligation reaction with lysine amide or arginine amide, or by lysine or arginine which is modified by protective groups, and optionally subsequent hydrolysis.Type: GrantFiled: January 7, 2009Date of Patent: April 2, 2013Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Frank Zocher
-
Patent number: 8119375Abstract: An improved method for preparing ramipril is disclosed, and also an intermediate for use in the method.Type: GrantFiled: June 19, 2008Date of Patent: February 21, 2012Assignee: Sanofi-Aventis Deutschland GmbHInventors: Holger Berk, Frank Zocher, Hans-Wolfram Flemming, Rainer Gauler, Rudolf Lehnert, Wolfgang Laux
-
Patent number: 8048854Abstract: The invention relates to insulin glargine which is modified by amidation, especially Gly(A21), Arg(B31), Arg amide (B32) human insulin (insulin glargine amide).Type: GrantFiled: January 7, 2009Date of Patent: November 1, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Frank Zocher
-
Patent number: 7981635Abstract: The present invention relates to the production of a variant of recombinant trypsin with increased substrate specificity for arginine versus lysine in non-animal host organisms. Moreover, the present invention relates to a variant of recombinant trypsin and their production. Also provided are use of recombinant porcine pancreatic trypsin variants for cleavage of precursors of insulins, and kits containing the variant of trypsin.Type: GrantFiled: August 26, 2006Date of Patent: July 19, 2011Assignees: Sanofi-Aventis Deutschland GmbH, Roche Diagnostics Operations, Inc.Inventors: Frank Zocher, Christoph Hoh, Rainer Mueller, Erhard Kopetzki, Frank Geipel, Stephan Glaser
-
Patent number: 7939293Abstract: The invention relates to the production of carboxy-terminal (C-terminal) amidified peptides with C-terminal amidified lysin, in particular with the biological activity of GLP-1, the chemical and/or biotechnological precursors and intermediate products thereof. The invention also relates to a method for the production and use thereof for producing pharmaceutical products.Type: GrantFiled: November 18, 2005Date of Patent: May 10, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Heinrich Decker, Claus Lattemann, Oliver Maneg, Christophe Salagnad, Frank Zocher
-
Publication number: 20100311112Abstract: The invention relates to a method for producing C-terminal amidated dibasic or polybasic peptides, consisting in reacting two peptides in the presence of trypsin biologically active enzymes and, if necessary, in purifying the thus obtainable compounds of formula (I) by means of protein chemistry.Type: ApplicationFiled: September 13, 2006Publication date: December 9, 2010Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Sebastian Rissom, Paul Habermann, Christophe Salagnad, Frank Zocher, Laure Landric-Burtin
-
Patent number: 7803950Abstract: The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.Type: GrantFiled: February 20, 2007Date of Patent: September 28, 2010Assignee: Sanofi-Aventis Deutschland GmbHInventors: Christophe Salagnad, Frank Zocher, Andreas Burgard, Bernd Junker, Rolf Hoerlein, Thomas Stuedemann, Claus-Jügen Maier, Jochen Hachtel, Wolfgang Holla, Christoph Tappertzhofen, Berndt Kulitzscher, Stephane Mutti
-
Publication number: 20100196953Abstract: The present invention relates to the production of a variant of recombinant trypsin with increased substrate specificity for arginine versus lysine in non-animal host organisms. Moreover, the present invention relates to a variant of recombinant trypsin and their production. Also provided are use of recombinant porcine pancreatic trypsin variants for cleavage of precursors of insulins, and kits containing the variant of trypsin.Type: ApplicationFiled: August 26, 2006Publication date: August 5, 2010Applicants: SANOFI-AVENTIS DEUTSCHLAND GMBH, F. HOFFMAN-LA ROCHE AGInventors: Frank Geipel, Stephan Glaser, Christoph Hoh, Erhard Kopetzki, Rainer Mueller, Frank Zocher
-
Publication number: 20090192073Abstract: The invention relates to a method for producing a type of insulin by genetically engineering a precursor thereof and converting said precursor to the respective insulin in an enzyme-catalyzed ligation reaction with lysine amide or arginine amide, or by lysine or arginine which is modified by protective groups, and optionally subsequent hydrolysis.Type: ApplicationFiled: January 7, 2009Publication date: July 30, 2009Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Paul HABERMANN, Frank ZOCHER
-
Publication number: 20090176692Abstract: The invention relates to insulin glargine which is modified by amidation, especially Gly (A21), Arg (B31), Arg amide (B32) human insulin (insulin glargine amide).Type: ApplicationFiled: January 7, 2009Publication date: July 9, 2009Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Paul HABERMANN, Frank ZOCHER
-
Publication number: 20090017509Abstract: An improved method for preparing ramipril is disclosed, and also an intermediate for use in the method.Type: ApplicationFiled: June 19, 2008Publication date: January 15, 2009Applicant: sanofi-aventis Deutschland GmbHInventors: Holger BERK, Frank ZOCHER, Hans-Wolfram FLEMMING, Rainer GAULER, Rudolf LEHNERT, Wolfgang LAUX
-
Publication number: 20090005299Abstract: The invention relates to the production of carboxy-terminal (C-terminal) amidified peptides with C-terminal amidified lysin, in particular with the biological activity of GLP-1, the chemical and/or biotechnological precursors and intermediate products thereof. The invention also relates to a method for the production and use thereof for producing pharmaceutical products.Type: ApplicationFiled: November 18, 2005Publication date: January 1, 2009Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Paul Habermann, Heinrich Decker, Claus Lattemann, Oliver Maneg, Christophe Salagnad, Frank Zocher
-
Publication number: 20080051583Abstract: The invention relates generally to intermediate compounds derived during the process for preparing diarylcycloalkyl derivatives which are activators for peroxisome proliferator-activated receptors (PPAR activators) and are therefore useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The intermediate compounds of the present invention are defined structurally by the formulae (Ia): and formula (II): wherein the respective substituent groups are defined herein.Type: ApplicationFiled: October 31, 2007Publication date: February 28, 2008Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Christophe Salagnad, Frank Zocher, Andreas Burgard, Bernd Junker, Rolf Hoerlein, Thomas Stuedemann, Claus-Jugen Maier, Jochen Hachtel, Wolfgang Holla, Christoph Tappertzhofen, Berndt Kulitzscher, Stephane Mutti
-
Publication number: 20070197614Abstract: The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.Type: ApplicationFiled: February 20, 2007Publication date: August 23, 2007Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Christophe Salagnad, Frank Zocher, Andreas Burgard, Bernd Junker, Rolf Hoerlein, Thomas Stuedemann, Claus-Jugen Maier, Jochen Hachtel, Wolfgang Holla, Christoph Tappertzhofen, Berndt Kulitzscher, Stephane Mutti
-
Patent number: 6828115Abstract: A description is given of epoxide hydrolases from bacteria of the genus Streptomyces, a novel process for the enzymatic separation of epoxide enantiomeric mixtures, of a novel detection method for epoxide hydrolase activity, a screening method for detecting epoxide hydrolase activity and the use of bacteria of the genus Streptomyces and of the resultant epoxide hydrolases for enantioselective epoxide hydrolysis.Type: GrantFiled: January 23, 2002Date of Patent: December 7, 2004Assignee: BASF AktiengesellschaftInventors: Frank Zocher, Markus Enzelberger, Rolf D. Schmid, Wolfgang Wohlleben, Bernhard Hauer